Over the past few years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes and recently have emerged as a promising therapeutic option for obesity [6]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.